FAQ: Cybin Inc. Presentation at H.C. Wainwright Global Investment Conference

What is the main announcement in this content?

Cybin Inc. announced that Chief Business Officer George Tziras will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 11:00 a.m. ET to discuss the company’s neuropsychiatry developments.

When and where is the H.C. Wainwright conference presentation taking place?

The presentation will occur on September 8, 2025, at 11:00 a.m. ET as part of the H.C. Wainwright 27th Annual Global Investment Conference, though the specific physical location is not detailed in the content.

Who is representing Cybin at the conference?

George Tziras, Cybin’s Chief Business Officer, will represent the company and participate in the fireside chat discussion at the investment conference.

What type of company is Cybin Inc.?

Cybin is a clinical-stage neuropsychiatry company developing next-generation treatment options for mental health conditions, with operations in Canada, the United States, the United Kingdom, and Ireland.

What are Cybin’s key development programs mentioned in the content?

Cybin is developing CYB003, a deuterated psilocin analog in Phase 3 studies for major depressive disorder, and CYB004, a deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder, both with proprietary formulations.

Where can investors find more information about Cybin’s latest updates?

Investors can access the latest news and updates relating to CYBN in the company’s newsroom at https://ibn.fm/CYBN and view the full press release about this conference presentation at https://ibn.fm/jkHN9.

What regulatory milestone has Cybin achieved for its CYB003 program?

CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential as a significant advancement in treating major depressive disorder.

Why is this conference presentation significant for investors?

This presentation provides investors with direct insights from Cybin’s leadership about the company’s clinical progress, pipeline developments, and strategic direction in the growing neuropsychiatry treatment market.